

[NeuMoDx HPV test gets CE mark](#)

written by CAP TODAY

September 18, 2020

September 2020—NeuMoDx Molecular has received the CE mark for its NeuMoDx HPV Assay, a fully automated, in vitro real-time PCR-based assay for the qualitative detection of high-risk types of human papillomavirus DNA in cervical specimens. It specifically identifies HPV 16 and 18 while concurrently detecting 13 other common high-risk types at clinically relevant infection levels.

The test was developed in collaboration with Self-screen BV (Amsterdam) and runs on the NeuMoDx 96 and NeuMoDx 288 molecular systems.

[NeuMoDx Molecular](#), 888-301-6639



©2026 CAP TODAY, all rights reserved.